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to this discovery, we searched for some AR enhancers to increase the efﬁcacy of Sorafenib chemotherapy, and
identiﬁed the microRNA (miR)-367-3p, whose expression is positively correlated with AR expression in ad-
vanced HCC, as an HCC metastasis suppressor. Combining miR-367-3p with Sorafenib showed better efﬁcacy
to suppress HCC cell invasion in vitro and in vivo. Mechanism dissection revealed that miR-367-3p could increase
AR expression via directly targeting the 3′UTR of MDM2 to decrease MDM2 protein expression. The resultant in-
crease of AR expression might then promote the expression of FKBP5 and PHLPP, thus dephosphorylating and
inactivating AKT and ERK, to suppress the HCC cell invasion. Interestingly, the suppression of pAKT by miR-
367-3p could subsequently attenuate the phosphorylation of AR and MDM2, giving rise to additional enhance-
ment of AR protein expression, effectively forming a positive feedback loop. Together, these results suggest
that miR-367-3p may function as an AR enhancer to increase Sorafenib chemotherapy efﬁcacy via altering the
MDM2/AR/FKBP5/PHLPP/(pAKT and pERK) signals to better suppress HCC metastasis. Successful development
of this newly combined chemotherapy in the future may help us to better suppress the HCC metastasis at late
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miR-367-3p1. IntroductionHepatocellular carcinoma (HCC) is listed as the ﬁfth and seventh
most frequently diagnosed cancer in men and women, respectively,
across the globe, and the most common primary liver tumor with in-
creasing incidence in the United States and elsewhere. With a dismal
outcome largely due to postsurgical recurrence and/or metastasis, HCC
is the third most common cause of cancer-related death worldwide
(Jemal et al., 2011; Siegel et al., 2012). Although targeted chemotherapy
with special target(s) has experienced a rapid progress in the recent de-
cade, themanagement of patients with advancedHCC, who become un-
qualiﬁed for liver transplantation or liver resection, is still far fromepartment of
10016, China.
, Departments
er, University
u (C. Chang).
under the CC BY-NCsatisfactory. Indeed, even patients who have received liver resection
often have a high frequency of metastasis/recurrence (Maluccio and
Covey, 2012). While clinical trials demonstrated that Sorafenib
prolonged the median overall survival time for 2.3–3 months in ad-
vanced HCC patients (Cheng et al., 2009), limited efﬁcacy with side ef-
fects demanded improvement of this therapy.
The androgen receptor (AR) is a ligand-dependent transcriptional
factor that belongs to the nuclear receptor superfamily. Androgen/AR
signals play important roles in normal liver function and in the develop-
ment of liver diseases including HCC (Ma et al., 2014). Previous studies
revealed amale predominance in HCC, which suggested that androgen/
AR signals may promote hepatocarcinogenesis (Yeh and Chen, 2010).
However, the results from several clinical trials using various anti-
androgens to treat HCC remain controversial (Groupe d'etude et de
traitement du carcinome, H., 2004; Matsuura et al., 1994; Chao et al.,
1996). Interestingly, Ma et al. revealed that AR might suppress
advanced-stage HCC metastasis using liver-speciﬁc deletion of AR (L-
ARKO) mice model and in vitro HCC cell lines, and over-expressing AR
with Sorafenib treatment could better suppress the HCC progression
at late stages (Ma et al., 2012). How to identify a potential molecule to-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ﬁcacy, however, remains to be further elucidated.
The microRNAs (miRNAs or miRs) are a group of small (around 22
nucleotides), non-coding RNA gene products existing in many organ-
isms that play crucial post-transcriptional regulatory roles in mRNA
translation and degradation by complementary base pairing, predomi-
nantly in the 3′-untranslated region (3′UTR) (Lau et al., 2001). The dis-
covery of miRNAs has increased our understanding of the post-
transcriptional regulation of genes and how this contributes to diverse
physiological, developmental, and pathophysiological processes, in-
cluding cancer initiation and progression (Wang et al., 2012). Several
studies have linked deregulation of miRNA expressions to HCC carcino-
genesis and metastasis in recent years (Budhu et al., 2008; Salvi et al.,
2013). Thus, miRNAsmay becomepromising candidates for therapeutic
targets. For example, Miravirsen, a miR-122 inhibitor that is already
used in clinical trials,was found to be safe and have nodose-limiting ad-
verse events or escape mutations in the miR-122 binding sites of the
HCV genome so far (Janssen et al., 2013).
Here we found miR-367-3p, whose expression is down regulated in
advanced HCC, might function as an invasion suppressor in advanced
HCC via altering theMDM2/AR/FKBP5/PHLPP/(pAKT and pERK) signals.
2. Materials and Methods
2.1. Materials
Sorafenib was purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). MK2206 was purchased from ApexBio (Houston, TX). MG132
(M8699) and Cycloheximide (CHX, 227048) were purchased from
Sigma-Aldrich (St. Louis, MO). MISSION® Synthetic miR-367-3p inhibi-
torwas purchased fromSigma-Aldrich also and transfected according to
the technical bulletin provided by the manufacturer.
2.2. Invasion Assay
Before invasion assays, HCC cells were seeded in 6-well plates at
5 × 105 (SKhep1, HepG2, Huh7 and SNU398) or 2 × 105 (HA22T and
SNU423) cells/well and we followed the designated treatments for
48 h. Then the cells were harvested by trypsinization and 3 × 104
HA22T cells, 5 × 104 SKhep1 and SNU423 cells, 1 × 105 HepG2, Huh7
and SNU398 cells in serum free DMEM were plated into the upper
chambers of transwells and 700 μl 10% FCS media was placed in the
lower chambers for 24 h incubation at 37 °C in 5% (v/v) CO2 incubator.
The upper chambers with 8 μm-pore-size polycarbonate membrane ﬁl-
ters (Corning, Inc., Corning, NY) were pre-coated with diluted growth
factor-reduced matrigel (1:14 serum free DMEM) (BD Biosciences).
After incubation, the cells on the upper layer of membranes were
scrapped out, and the cells invaded to the lower membrane were
stained with 0.1% (w/v) crystal violet. The invaded cells were counted
in ten randomly chosen microscopic ﬁelds (100×) in each experiment
and averaged for quantiﬁcation. Each sample was run in triplicate and
multiple experiments were performed.
2.3. 3D Invasion Assay
Brieﬂy, 5 × 104 of cells in 3 ml media containing 2.5% Matrigel and
30ng epidermal growth factor (EGF)were plated into collagen/Matrigel
mixture coated plate. The media were replenished every 3 days for 10–
12 days. The cells with protrusions were regarded as invaded cells and
10 random different ﬁelds under 200× magniﬁcation were counted
for quantiﬁcation.
2.4. Luciferase Assay
540 bp fragments of MDM2 3′UTR containing wild type or mutant
miRNA-responsive elements (Sequences listed on SupplementaryTable 1) were cloned into the psiCheck2 construct (Promaga, Madison,
WI) downstream of the Renilla luciferase ORF. Cells were plated in 24-
well plates and the cDNA were transfected using Lipofectamine 3000
(Invitrogen) according to themanufacturer's instructions. Luciferase ac-
tivity was measured by Dual-Luciferase Assay (Promega) according to
the manufacturer's manual.
2.5. Tissue Samples
The current study conformed to the principles of the Declaration of
Helsinki and was approved by the Institutional Review Board of the
Sir Run-Run Shaw Hospital. A total of 126 randomly selected HCC clini-
cal samples (102 parafﬁn-ﬁxed and 24 freshly frozen samples) were
collected from the Department of General Surgery, Sir Run-Run Shaw
Hospital, Zhejiang University starting in February 2006,with all patients
signing Informed Consent for the use of their tissues for scientiﬁc re-
search. We reviewed pathology records to identify samples with con-
ﬁrmed HCC. The demographic and clinical information of the patients
were listed in Table 1.
2.6. In Vivo Studies
32 6–8weeks old athymic nudemalemicewere purchased fromNCI
and randomized into 4 groups with standard housing and husbandry.
SKhep1 cells were prepared as stable luciferase clones by infection
with pLKO-Luciferase lentivirus and pLKO.1-shGFP or pLKO.1-miR-
367-3p. Intrahepatic injections of 1 × 106 SKhep1-luc cell lines/100 μL
serum-freeDMEMandmatrigel (1:1)were performed inmice in groups
as follows: 1) SKhep1-luc-shGFP + vehicle; 2) SKhep1-luc-miR-367-
3p + vehicle; 3) SKhep1-luc-shGFP + Sorafenib; and 4) SKhep1-luc-
miR-367-3p + Sorafenib. After 1 month, the mice were treated with/
without Sorafenib (30 mg/kg/mice; daily, oral gavage) as indicated for
another month. Sorafenib (for groups 3 and 4) was suspended in an
oral vehicle containing Cremophor (Sigma-Aldrich), 95% ethanol and
water in a ratio of 1:1:6. All control mice (groups 1 and 2) received an
equal volume of carrier solution by gavage. Tumor development and
metastasis wasmonitored by IVIS once a week starting after drug treat-
ment following intraperitoneal injection of 150mg/kg D-Luciferin.Mice
were sacriﬁced after 4 weeks of treatment and tumors were removed
for studies. All animal studies were performed under the supervision
and guidelines of the University of Rochester Medical Center Animal
Care and Use Committee, and experiments were adjusted to minimize
suffering and to use the smallest number of animals that could obtain
statistical results.
2.7. Statistical Analysis
Data are expressed as mean ± SEM from at least 3 independent ex-
periments. Statistical analyses involved Student's t-test, Log-rank (Man-
tel-Cox) test, Kolmogorov-Smirnow test, Mann-Whitney U Test and
Spearman rank correlationwith GraphPad Prism5 (GraphPad Software,
Inc., La Jolla, CA). p b 0.05 was considered statistically signiﬁcant. The
Western blot bands were analyzed by Gel-Pro analyzer (Meyer Instru-
ments, Inc., Houston, TX) and shown on Supplementary Fig. 5. More de-
tailed materials and methods information please see Supplementary
Materials and Methods.
3. Results
3.1. AR Suppresses HCC Cell Invasion
Early in vivomice studies suggested that hepatic AR could function
as a late-stage HCC metastasis suppressor (Ma et al., 2012). In the pres-
ent study, we examined AR's effect on the invasion of various HCC cell
lines using chamber invasion assays. Results revealed that over-
expression of AR decreased the cell invasion in all 3 HCC cell lines
ac
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Fig. 1. AR suppresses HCC cells invasion. (a), veriﬁcation of AR over-expression by western blot assays; (b), chamber-transwell invasion assays showed that over-expression of AR
decreased the cell invasion in all 3 HCC cell lines (SKhep1, HA22T, and HepG2). Upper panel, representative images of the chamber-transwell invasion assays; Lower panel,
quantiﬁcation of the invaded cells. The invaded cells were counted in 10 randomly chosen microscopic ﬁelds (100×) of each experiment and pooled. Each sample was run in triplicate
and multiple experiments were performed. (c-d), 4 individual research databases clearly showed that AR levels were lower in advanced stages compared with early stages, implicating
that AR played a vital role in late-stage HCC and was negative correlated with HCC metastasis. Data were extracted from Oncomine® Platform (c) and Gene Expression Omnibus
Datasets (d). (e), the average AR IHC staining scores of patients were evaluated by experienced pathologists both in high-invasive group (N = 13) and low-invasive group (N = 89).
Lower AR IHC staining scores were found in high-invasive group as compared to those found in low-invasive group. (f), recurrence-free survival curve of HCC patients who received
surgery (N = 92) indicated that patients with HCC (AR+) (deﬁned by IHC staining) had signiﬁcant higher recurrence-free survival (HR = 0.3711) than patients with HCC (AR-).
p b 0.05 was considered statistically signiﬁcant. * p b 0.05 and ** p b 0.01.
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Fig. 2. The miR-367-3p increases AR protein levels and is expressed at lower levels in late-stage HCC. (a), western blot assays were applied to check the AR protein levels after over-
expressing the 8 miRNA candidates according to the screening strategy in SKhep1 and HA22T cell lines. (b), upper panel: AR levels in 4 different HCC cell lines (SKhep1, HA22T,
HepG2, and Huh7) with overexpressed miR-367-3p were checked by western blot assays and were found consistently and signiﬁcantly increased; lower panel: veriﬁcation of miR-
367-3p over-expression by qRT-PCR. (c), miR-367-3p was expressed at lower levels in metastatic patients than non-metastatic patients according to the non-coding RNA microarray
data submitted on public Gene Expression Omnibus Datasets. (d), parafﬁn-ﬁxed clinical sample surveys disclosed a signiﬁcantly higher miR-367-3p expression in patients with HCC
(AR+, N = 65) than in those with HCC (AR-, N = 27). HCC (AR+) and HCC (AR-) were determined by IHC staining. (e), recurrence-free survival curve of HCC patients who received
surgery (N = 92) indicated that patients with higher miR-367-3p expression had signiﬁcantly higher recurrence-free survival (HR = 0.4523) than patients with lower miR-367-3p
expression. (f), left panel: freshly frozen clinical samples showed a signiﬁcantly higher miR-367-3p expression in patients with HCC (AR+, N = 17) than in those with HCC (AR-, N =
7). HCC (AR+) and HCC (AR-) were determined by IHC staining; right panel: correlation analysis of miR-367-3p and AR mRNA levels from 24 HCC samples by qRT-PCR indicated a
signiﬁcant positive correlation between miR-367-3p and AR mRNA levels. p b 0.05 was considered statistically signiﬁcant. * p b 0.05 and *** p b 0.001.
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59J. Xu et al. / EBioMedicine 12 (2016) 55–67(SKhep1, HA22T, andHepG2) (Fig. 1a-b), suggesting that AR could func-
tion as a late-stage HCCmetastasis suppressor and is in agreement with
the previous study (Ma et al., 2012).
Importantly, multiple HCC transcriptome analyses (Fig. 1c–d) dem-
onstrated that AR expression was lower in advanced stages compared
with early stages of HCC (Liao et al., 2008; Minguez et al., 2011;
Wurmbach et al., 2007; Chiang et al., 2008), implicating that AR played
a vital role in late-stage HCC and was negatively related with HCC
metastasis.
To further conﬁrm the conclusion above, we performed IHC staining
of AR on the clinical samples collected from HCC patients who received
surgery. We used multiple tumor foci, satellite nodules, micro-vascular
invasion and portal vein tumor thrombosis, to deﬁne/classify these pa-
tients into 2 groups: high-invasive (patients with either multiple
tumor foci, satellite nodules, micro-vascular invasion, portal vein
tumor thrombosis, or combinations of these) and low-invasive (pa-
tients with neither multiple tumor foci, satellite nodules, micro-
vascular invasion nor portal vein tumor thrombosis). The results indi-
cated that lower AR IHC staining scores were found in high-invasive
group as compared to those found in low-invasive group (Fig. 1e), sug-
gesting that AR might relate negatively with HCC metastasis at late
stages. Importantly, it was also found that patients with positive AR
(AR+) HCC (as deﬁned by IHC staining) had signiﬁcant higher
recurrence-free survival (HR = 0.3711) than patients with negative
AR (AR-) HCC (Fig. 1f).
Together, results from Fig. 1 suggest that AR may act as a late-stage
HCC metastasis suppressor.
3.2. The miR-367-3p Increases AR Protein Expression in Late-stage HCC
Since AR serves as an HCC suppressor at late stages, we were inter-
ested in targeting AR via some potential molecules that could increase
or stabilize AR expression in order to provide potential therapies to bet-
ter ﬁght HCCmetastasis. We focused on thosemiRNAs related to the E3
ligases thatmight alter theARdegradation.Weﬁrst developed a speciﬁc
screening strategy to seek for AR expression enhancers. According to re-
cent literature (Lin et al., 2002; Dirac and Bernards, 2010; Li et al., 2008;
Rees et al., 2006; An et al., 2014; Nishida and Yasuda, 2002), we picked 7
E3 ligases that could target AR and enhance AR degradation. From data-
bases (TargetScan, miRDB and MicroCosm Targets) analyses, we found
limited potential candidates and focused on 8miRNAs that might possi-
bly increase AR expression according to the databases prediction (Sup-
plementary Fig. 1a). We then over-expressed these miRNAs in SKhep1
and HA22T cell lines to examine their effects on AR expression. As
shown in Fig. 2a, the presence of miR-367-3p, miR-513a-3p, and miR-
944 signiﬁcantly increased the AR expression in SKhep1 cells; however,
AR expression could only be elevated by miR-367-3p and miR-377-3p
in HA22T cells.
We then focused on miR-367-3p as it could up-regulate AR expres-
sion in both HCC cell lines, and further conﬁrmed these ﬁndings in 4
HCC cell lines (SKhep1,HA22T,HepG2, andHuh7), showing a consistent
increase of AR expression upon over-expressing miR-367-3p (Fig. 2b).
Interestingly, based on public Gene Expression Omnibus Datasets sub-
mitted by Budhu A et al. (Budhu et al., 2008) that contained the largest
sample size related to HCC metastasis, we found that miR-367-3p was
expressed lower in metastatic HCC patients as compared to those in
non-metastatic HCC patients (Fig. 2c). Similarly, miR-302a/b/c/d, mem-
bers of themiR-302/367 cluster, which are located in the same genomic
region and share the same promoter (Sewer et al., 2005), also had lower
expressions in metastatic HCC patients (Supplementary Fig. 1b), indi-
cating this down-regulation in the advanced stage of HCCmight be con-
trolled or modiﬁed by the shared promoter of the miR-302/367 cluster.
Moreover, 6 HCC cell lines were divided into 2 groups based on their in-
vasive abilities (Supplementary Fig. 1c-d, Group I: high invasive; Group
II: low invasive), and we found that the expression of miR-367-3p was
signiﬁcantly lower in Group I compared to Group II, which furthersupported the role of miR-367-3p as an HCC metastasis suppressor
(Supplementary Fig. 1e).
Parafﬁn-ﬁxed clinical sample surveys disclosed a signiﬁcantly higher
miR-367-3p expression in patients with HCC (AR+) than in those with
HCC (AR-) (Fig. 2d). Importantly, results showed that patients with
higher miR-367-3p expression had signiﬁcant higher recurrence-free
survival (HR = 0.4523) than patients with lower miR-367-3p expres-
sion (Fig. 2e). Moreover, frozen clinical samples also showed signiﬁ-
cantly higher miR-367-3p expression in patients with HCC (AR+)
than in those with HCC (AR-) (Fig. 2f, left panel). In addition, we also
found a signiﬁcant positive correlation between miR-367-3p and AR
mRNA expression, which strongly supported our ﬁndings in 4 different
HCC cell lines (Fig. 2f, right panel).
Together, results from Fig. 2 and Supplementary Fig. 1 suggest that
miR-367-3p, which is lower expressed and positively correlates with
AR expression in late-stage HCC, may increase AR protein levels in HCC.
3.3. The miR-367-3p Suppresses HCC Cell Invasion via Altering the AR-
FKBP5-PHLPP-(pAKT and pERK) Signals
To further verify the positive correlation between miR-367-3p and
AR expression and their impacts on HCC progression at late stages, we
performed the chamber-transwell invasion assays on 2 invasive HCC
cell lines (SKhep1 and HA22T) and the results showed that over-
expression of miR-367-3p could signiﬁcantly decrease (Fig. 3a, upper
panel), while miR-367-3p inhibitor could signiﬁcantly increase the in-
vasion ability of bothHCC cell lines (Fig. 3a, lower panel). Similar results
were also obtained when we replaced the chamber-transwell invasion
assay with the 3D invasion assay in both SKhep1 and HA22T cells
(Fig. 3b).
To dissect the potentialmolecularmechanism,we ﬁrst hypothesized
that miR-367-3p might regulate some AR-modulated metastasis-
related genes, such as pAKT, TGFβ1, COX-2, NF-κB and p27, as recent
studies indicated that these AR-modulated genesmight be able tomedi-
ate the AR-suppressed cell invasion in prostate cancer (Niu et al., 2008).
In a pilot study, we found miR-367-3p could signiﬁcantly decrease
TGFβ1 expression and decrease AKT activity (by inhibiting phosphory-
lation of Akt in Ser-473) in both SKhep1 and HA22T cells (Fig. 3c), but
not for the other genesmentioned above (Supplementary Fig. 2a). How-
ever, TGFβ1 expression changed inconsistently in SKhep1 and HA22T
cells with AR knocked down, suggesting the roles of TGFβ1 in these
cells might be limited (Supplementary Fig. 2b).
We then examined other potential metastasis-related genes and
found that the expression of PHLPP (PH domain and Leucine rich repeat
Protein Phosphatases), which could inhibit the phosphorylation of AKT
through different signaling components (Brognard et al., 2007), was in-
creased (Fig. 3c), whereas the expression of other metastasis-related
genes remained unchanged or inconsistently changed (Supplementary
Fig. 2a). These results suggested that miR-367-3pmight be able to func-
tion through increasing PHLPP expression to dephosphorylate AKT at
Ser-473 to decrease AKT activity. Furthermore, a previous study sug-
gested that p-ERK could also be regulated by PHLPP (Li et al., 2014),
and we indeed found p-ERK (Thr202/Tyr204) signiﬁcantly decreased
when over-expressing miR-367-3p (Fig. 3c). The enhanced de-
phosphorylation by PHLPP is likely facilitated by FKBP5 that functions
as a scaffold to enhance the PHLPP-AKT interaction and PHLPP-
mediated de-phosphorylation (Brognard and Newton, 2008; Pei et al.,
2009). In our study, FKBP5 was signiﬁcantly increased upon AR eleva-
tion by miR-367-3p as it is known that FKBP5 is a transcription target
of AR. (Fig. 3c).
An interruption approach via knocking down AR revealed that a re-
duction of AR partially reversed the expression of FKBP5, PHLPP, pAKT
(S473) and p-ERK (Thr202/Tyr204), and miR-367-3p could no longer
signiﬁcantly inhibit pAKT (S473) and p-ERK (Thr202/Tyr204) in AR
knocked-downHCC cells (Fig. 3d). The rescue assay for invasion showed
the inhibition of invasion by miR-367-3p in SKhep1 cells was
Fig. 3. The miR-367-3p suppresses HCC cell invasion via altering the AR/FKBP5/PHLPP/(pAKT and pERK) signals pathway. (a), chamber-transwell invasion assays on SKhep1 and HA22T
cell lines showed that over-expression of miR-367-3p could signiﬁcantly decrease, while miR-367-3p inhibitor could signiﬁcantly increase the invasion ability. The invaded cells were
counted in 10 randomly chosen microscopic ﬁelds (100×) of each experiment and pooled for quantiﬁcation. (b), 3D-invasion assays on SKhep1 and HA22T cell lines also showed that
over-expression of miR-367-3p could signiﬁcantly decrease the invasion ability. The cells with protrusions were regarded as invaded cells and 10 random different ﬁelds at 200×
magniﬁcation were counted for quantiﬁcation; (c), we used western blot assays to test downstream altered molecules upon over-expressing miR-367-3p in SKhep1 and HA22T cells.
(d, e), rescue assays by knocking down AR showed partially reversed FKBP5-PHLPP-(pAKT/pERK) levels (by western blot assays) and cell invasion ability (by chamber-transwell
invasion assays). (f), we used western blot assays to test downstream altered molecules upon transfecting miR-367-3p inhibitor (50 nM) in SKhep1 and HA22T cells.
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Table 1
Demographic and clinical information of the patients.
Parafﬁn samples Frozen samples
Total 102 24
Gender Male 84 19
Female 18 5
Age b50 35 3
≥50 67 21
Multinodular Yes 5 2
No 97 22
Tumor size (cm) b5 61 15
≥5 41 9
Cirrhosis Yes 62 14
No 40 10
Metastasis Yes 13 9
No 89 15
ALT (IU/L) Normal⁎ 75 12
Abnormal⁎ 37 12
AFP (μg/L) Normal⁎⁎ 48 13
Abnormal⁎⁎ 56 11
Child-Pugh Class A 97 21
B 5 3
BCLC stage 0 15 0
A 73 13
B 1 2
C 13 9
HBV Yes 85 19
No 17 5
HCV Yes 0 0
No 102 24
Schistosomiasis Yes 3 1
No 99 23
Fatty liver Yes 5 3
No 97 21
All the information were collected before the surgery.
⁎ Normal: ALT ≤ 50 IU/L; Abnormal: ALT N 50 IU/L.
⁎⁎ Normal: AFP ≤ 25 μg/L; Abnormal: AFP N 25 μg/L.
Table 2
IHC grades of AR and pERK/pAKT from 102 clinical HCC samples.
IHC grade AR
− + ++ +++
pERK⁎ − 3 2 10 23
+ 4 8 6 3
++ 2 3 15 11
+++ 3 5 1 3
pAKT⁎⁎ − 3 2 10 23
+ 4 8 6 3
++ 2 3 15 11
+++ 3 5 1 3
Each IHC slide was checked and the IHC grades were determined by a specialized
pathologist.
⁎ Spearman rank correlation: r =−0.2613, p= 0.0080.
⁎⁎ Spearman rank correlation: r =−0.2047, p= 0.0390.
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also obtained whenwe replaced SKhep1 cells with HA22T cells, indicat-
ing this newly identiﬁed signal is not unique to a particular cell line
(Fig. 3e).
Importantly, expected changes in the signaling components were
demonstrated in SKhep1 and HA22T cells in response to the inhibitor
of miR-367-3p (Fig. 3f), which further proved miR-367-3p could regu-
late AR-FKBP5-PHLPP-(pAKT and pERK) signaling pathway to inhibit
the cell invasion of HCC. Consistent with the in vitro ﬁndings, a clinical
sample survey also showed a negative correlation of pAKT/pERK and
AR in HCC patients (Table 2; Supplementary Fig. 2c). (See Table 1.)
Together, results from Table 1, Fig. 3 and Supplementary Fig. 2 sug-
gest that miR-367-3p may be able to suppress HCC cell invasion via in-
creasingAR expression that results inmodulating theAR-FKBP5-PHLPP-
(pAKT and pERK) signaling pathway.
3.4. Mechanism Dissection How miR-367-3p Increases AR Expression
To further dissect themolecularmechanism(s) howmiR-367-3p in-
creases AR expression, according to the screening strategy and bioinfor-
matics analysis, we focused on the 2 miR-367-3p predicted targets,
MDM2 and USP26 (Supplementary Fig. 1a), that were reported tomod-
ulate AR protein expression. We found MDM2 was consistently de-
creased in these 3 HCC cell lines (SKhep1, HepG2 and HA22T),
whereas USP26 showed a slight increase after over-expression of miR-
367-3p (Fig. 4a). Moreover, the transcript levels of MDM2 were consis-
tently decreased after 7 days expression of exogenous miR-367-3p
(Fig. 4b left panels). Interestingly, we also found AR mRNA levels de-
creased after over-expression of miR-367-3p (Fig. 4b right panels),
thus were incompatible with increased AR protein levels while
supporting a post-transcriptional/translational upregulation of AR in re-
sponse to miR-367-3p. This mechanism is entirely consistent withmiR-
367-3p-mediated suppression of MDM2, which degrades AR in a
proteasome-dependent manner. With regard to the decrease of AR
mRNA levels upon over-expressing miR-367-3p, we speculated that
miR-367-3p might have several other targets, which resulted in alter-
ation of AR mRNA transcription. In addition, the post-translational reg-
ulation of AR by MDM2 resulted in consistent increases in AR protein
levels. Indeed, in the 3 HCC cell lines, we found the miR-367-3p inhibi-
tor could signiﬁcantly increaseMDM2 and decrease AR at a protein level
(Fig. 4c). Furthermore,we found the expression ofmiR-367-3p could in-
crease AR protein stability when treated with cyclohexane (CHX)
(Fig. 4d) and decrease AR ubiquitination when treated with MG132, a
speciﬁc potent, reversible, and cell-permeable proteasome inhibitor
that reduces the degradation of ubiquitin-conjugated proteins in mam-
malian cells (Fig. 4e). Importantly, we applied the interruption ap-
proach via over-expressing MDM2, and results revealed that increased
MDM2 could signiﬁcantly decrease AR and could partially abolish the
miR-367-3p-increased AR protein expression (Fig. 4f), indicating that
miR-367-3p could increase AR protein levels via altering the MDM2-
mediated AR ubiquitination and degradation.
To further conﬁrm that theMDM2gene is a direct target ofmiR-367-
3p tomediate its downstream events, we constructed two luciferase re-
porter constructs that bear the miR-367-3p target site in the 3′UTR of
MDM2 gene as well as the attendant construct carrying the mutation
in the target sequence (Fig. 5a). As expected, the luciferase assay results
indicated that miR-367-3p could decrease MDM2 3′UTR #1 constructs
containing the wild type (WT) but not the mutated (M) site (Fig. 5b),
suggesting miR-367-3p might directly target the MDM2 3′UTR to in-
duce its mRNA degradation (Djuranovic et al., 2012). On the other
hand, miR-367-3p could not regulate MDM2 3′UTR #2 construct either
with WT or M target sequences, suggesting that the surrounding se-
quence context might contribute to the efﬁcacy of microRNA (Fig. 5c).
Early studies suggested thatMDM2-mediated and phosphorylation-
dependent AR ubiquitination plays key roles for AR to be degraded by
the proteasome (Lin et al., 2001; Lin et al., 2002). Thus, we applied theMK2206, a highly selective inhibitor of AKT1/2/3, which inhibits the
phosphorylation of AKT (Ser473) that could then inﬂuence MDM2 pro-
tein expression via suppressing MDM2 phosphorylation (S166) (Lin
et al., 2002), and examined its effects on AR protein expression in re-
sponse to MDM2 expression. As expected, MK2206 suppressed MDM2
phosphorylation and increased the AR protein expression in 3 HCC cell
lines (Fig. 5d), suggesting a repression of AKT activity could result in in-
creased AR protein expression, mimicking the decreased phosphoryla-
tion of AKT by a higher expression of miR-367-3p. Moreover, we
constructed pWPI-myr-Akt-Δ4-129-HA to over-express active AKT in
HCC cells and found signiﬁcant increases of pMDM2 (S166) and de-
creases of AR (Fig. 5e). Hence, the suppression of pAKT by miR-367-3p
could subsequently attenuate the phosphorylation of AR and MDM2,
giving rise to additional enhancement of AR protein levels, effectively
forming a positive feedback loop (Fig. 5f).
Fig. 4. The miR-367-3p mediates AR protein stability and ubiquitination via targeting MDM2. (a), we used western blot assays to test MDM2, USP26 and AR protein levels upon over-
expressing miR-367-3p and found MDM2 was consistently decreased in these 3 HCC cell lines (SKhep1, HepG2 and HA22T), whereas USP26 increased slightly after over-expression of
miR-367-3p. (b), left panels, transcript levels of MDM2 were consistently decreased after 7 days exogenous expression of miR-367-3p. Right panels, AR mRNA levels decreased after
over-expression of miR-367-3p. MDM2 and AR mRNA levels were determined by qRT-PCR. (c), miR-367-3p (50 nM) inhibitor could signiﬁcantly increase MDM2 and decrease AR at
protein levels as shown by western blot assays. (d), the expression of miR-367-3p could increase AR protein stability as determined by western blot assays after cycloheximide (CHX)
treatment for 0, 1, 2, 3, 6, and 12 h. (e), in AR over-expressed SKhep1 cells, the expression of miR-367-3p could decrease AR ubiquitination as determined by immunoprecipitation
(AR) and western blot (ubiquitin) after 3 h 20 μMMG132 treatment. (f), interruption approach via over-expressing MDM2 revealed that increased MDM2 could signiﬁcantly decrease
AR expression and could partially abolish miR-367-3p-increased AR protein expression.
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function through p53 because of the well-known connection between
MDM2 and p53. In this study, we also checked the p53 levels upon
miR-367-3p over-expression and results showed that the p53 de-
creased in SKhep1 and had little change in HA22T cells (Supplementary
Fig. 3a), which indicated that p53 might unlikely to play a role in the
case of invasion in terms of HCC.
Together, results from Figs. 4 and 5 and Supplementary Fig. 3a sug-
gest that miR-367-3p could directly target the 3′UTR of MDM2 to de-
crease MDM2 expression that results in increased AR expression and
subsequently generates a positive feedback loop resulting in further
augmentation of AR expression.
3.5. The miR-367-3p Increases Sorafenib Efﬁcacy to Better Suppress HCC
Metastasis Both In Vitro and In Vivo
While the current HCC therapywith Sorafenib showed survival ben-
eﬁts in Phase III clinical studies (Llovet et al., 2008; Cheng et al., 2009),
many HCC patients still failed to respond, or suffered from side effects
or developed resistance after being treated for several months
(Villanueva and Llovet, 2011; Berk et al., 2013). Interestingly, a recent
study indicated that a moderate dose of Sorafenib (5 μM) could be sen-
sitized with exogenous expression of AR that resulted in better efﬁcacy
to suppress HCC progression at late stages (Ma et al., 2012). However,
using potential molecules to increase AR expression to enhance the So-
rafenib chemotherapy efﬁcacy remains elusive. We hypothesized that
introducingmiR-367-3p to increase AR expressionmight be able to sen-
sitizeHCC to Sorafenib chemotherapy.We ﬁrst demonstrated that over-
expression of miR-367-3p enhanced Sorafenib efﬁcacy to suppress
SKhep1 and HA22T cell invasion compared to Sorafenib or miR-367-
3p alone (Fig. 6a), indicating that the combination of Sorafenib and
miR-367-3p might provide a new robust approach to better treat
advanced-stageHCCpatients. Interestingly, we noticed that undermod-
erate Sorafenib chemotherapy, miR-367-3p could signiﬁcantly increase
AR, FKBP5 and PHLPP expressions, therefore inhibit p-Akt (S473) and p-
ERK (Thr202/Tyr204) in both cell lines, suggesting a potential positive
feed-back mechanism to further increase the combined
(Sorafenib + miR-367-3p) therapy efﬁcacy (Fig. 6b).
To verify the efﬁcacy in vivo of the combined therapy characterized
in HCC cell lines in vitro, we applied orthotopic HCC xenografts in a
mousemodel.We found lower intra-hepatic and lungmetastasis occur-
rence inmiR-367-3p-expressing group than control groupwith orwith-
out Sorafenib treatment (Fig. 6c left and middle panel, Fig. 6d and
Supplementary Fig. 4a-b). Signiﬁcantly, we also demonstrated less
total metastatic foci and total tumor burden (determined by total pho-
ton ﬂux) in miR-367-3p-expressing group than control group with or
without Sorafenib treatment (Fig. 6c right panel, Fig. 6e). Consistent
with the ﬁndings in vitro, through IHC staining of AR, pAKT and pERK
in the tumors formed in these mice, we found a similar signaling trans-
duction regulated by miR-367-3p expression (Fig. 6f).
4. Discussion
HCC represents the most common histological subtype among pri-
mary liver cancers and the leading cause of death among patients
with cirrhosis, accounting for 70% to 85% of the total liver cancer burden
worldwide (Perz et al., 2006; Alazawi et al., 2010). Increasing incidence
of HCC around the world, especially in the United States and Central
Europe, allows a more profound understanding of the cancer progres-
sion and propelled a rapid development of life-prolonging therapies.
With advances in liver surgery and transplantation in the past few de-
cades, curative treatment can now be offered to HCC patients with
liver resection and regeneration if diagnosed early enough or those
who meet the transplant criteria, yielding over 50% 5-year survival
rate through the two surgical treatments (Asham et al., 2013).However, for late-stage HCC patients with poor liver functions who
cannot tolerate liver resection or transplantation, several local-
regional therapies such as tumor ablation, TACE and radiation therapies
are available. Moreover, systemic chemotherapy and molecularly
targeted therapies also yield promising results. Among these, Sorafenib,
the ﬁrst effective drug approved by the FDA, represented a milestone in
the therapy for HCC, especially for the patients at late stages. Nonethe-
less, irresponsiveness and resistance along with undesired side effects
of Sorafenib suggest the need for more and better efﬁcacious drugs
with fewer side effects.
In the past years, efforts have been made to dissect mechanisms by
which targeting AR could inhibit HBV- and carcinogen-induced early-
stage HCC development (Wu et al., 2010). Nevertheless, clinical trials
using various anti-androgens in the attempt to treat HCC have inconsis-
tent conclusions (Groupe d'Etude et de Traitement du Carcinome, 2004;
Matsuura et al., 1994; Chao et al., 1996). Several hypotheses have been
proposed to elucidate this riddle, such as the fact that most of the anti-
androgen therapies were developed to reduce/antagonize androgens
from binding to AR, but not to target AR itself. Recently, the dual roles
of AR in HCC were demonstrated showing AR might function as a stim-
ulator to promote HCC initiation and development at early stages, yet
might function as a metastasis suppressor in the advanced stages of
HCC, implying that targeting AR should be stage-dependent (Ma et al.,
2012). Importantly, results from in vivomouse model studies also indi-
cated that increased AR expression with a moderate dose (5 μM) of So-
rafenib might result in higher efﬁcacy of HCC suppression at late stages.
Furthermore, supported by data from cell line studies in vitro, mouse
model studies in vivo, bioinformatic analyses and human clinical evi-
dences, the present study provides clearer evidences that AR indeed
acts as a metastasis suppressor in late-stage HCC. It remains to be seen
whether activation of AR through hormone stimulation is equal to
lentiviral induction of AR expression, thus a clinical application of
these ﬁndings could be beneﬁcial for patients with late stages of liver
cancer.
Alternatively, identifying potential molecules to increase AR expres-
sion in order to enhance Sorafenib chemotherapy efﬁcacy could be one
choice and remains to be explored. Growing evidences indicate that the
deregulation of miRNAs plays a vital role in HCC onset as well as pro-
gression. The diagnostic, prognostic, and even therapeutic values of
HCC related miRNAs have also been widely discussed. At advanced
stages, severalmiRNAs associated with HCC venousmetastasis were re-
ported to be up-regulated or down-regulated (Budhu et al., 2008). Sev-
eral studies further developed miRNA-based classiﬁcation of HCC
subclasses (Toffanin et al., 2011), miRNA-based risk assessment of
HCC recurrence after liver resection (Sato et al., 2011), and miRNA-
based prediction and alteration of sensitivity to chemotherapeutics
and molecularly targeted therapies (Bai et al., 2009; Zhou et al., 2011).
Furthermore, accumulating studies focusing on miRNA therapies in
HCC indicated that, either introducing the oncosuppressor miRNAs or
inhibiting oncomiRs resulted in impaired growth or invasion ability
in vitro by HCC cell lines, in vivo in animal xenografts models, and
even in clinical trials (Kota et al., 2009; Lanford et al., 2010; Callegari
et al., 2012). Miravirsen (SPC3649), the ﬁrst anti-miR drug candidate,
is currently in clinical testing for treatment of HCV infections. Targeting
miR-122, a liver-speciﬁc miRNA with an important role in the life cycle
of hepatitis C virus (HCV), Miravirsen monotherapy provides long-
lasting suppression of viremia, has a high barrier to viral resistance,
and is well tolerated in patients with chronic HCV infection (Lindow
and Kauppinen, 2012). This break-through encouraged us to seek for
new miRNA targets as novel therapeutics, especially combining with
Sorafenib, to better control HCC progression.
In this study, we identiﬁed miR-367-3p, whose expression is posi-
tively correlated with AR expression and expressed at lower levels in
advanced human HCC, as an HCC metastasis suppressor. These ﬁndings
are supported by solid clinical data and had established a foundation for
a potential use of miRNA for late-stage HCC. Importantly, we identiﬁed
Fig. 5. The miR-367-3p directly targets the 3′UTR of MDM2 to mediate AR levels and subsequently generates a positive feedback loop. (a), MDM2 3′UTR containing wild type (WT) or
mutant (M) miRNA-response elements were cloned into the psiCheck2 construct downstream of the Renilla luciferase ORF, (b), co-transfection of MDM2 3′UTR constructs containing
WT seed regions with pLKO.1-miR-367-3p decreased the luciferase activity and with miR-367-3p inhibitor increased the luciferase activity, whereas the reporter with a M seed region
in MDM2 3′UTR did not, in the ﬁrst predicted miR-367-3p seed regions. (c), co-transfection of MDM2 3′UTR constructs containing WT seed regions with pLKO.1-miR-367-3p or with
miR-367-3p inhibitor (50 nM) could not alter the luciferase activity, neither did the reporter with a M seed region in MDM2 3′UTR, in the second predicted miR-367-3p seed regions.
(d), western blot assays showed that MK2206 (1 μM in SKhep1 and HA22T cells, 2.5 μM in HepG2 cells) suppressed MDM2 phosphorylation and increased the AR protein expression
at various time points. (e), over-expressing pWPI-myr-Akt-Δ4-129-HA in HCC cells showed signiﬁcant increases of pMDM2 (S166) and decreases of AR. (f), the schematic depiction
showing the suppression of pAkt by miR-367-3p could subsequently attenuate the phosphorylation of AR and MDM2, giving rise to additionally increased AR protein levels, which
formed a positive feed-back circuitry. p b 0.05 was considered statistically signiﬁcant. * p b 0.05, ** p b 0.01, and *** p b 0.001.
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Fig. 6. Sorafenib andmiR-367-3p serve as a better combination therapy to suppress HCCmetastasis in vitro and in vivo. (a), chamber-transwell invasion assays showed the combination of
Sorafenib and miR-367-3p exhibited better efﬁcacy to suppress SKhep1 and HA22T cells invasion compared to Sorafenib or miR-367-3p alone. The invaded cells were counted in 10
randomly chosen microscopic ﬁelds (100×) of each experiment and pooled for quantiﬁcation. (b), western blot assays showed that under moderate Sorafenib chemotherapy, miR-
367-3p could signiﬁcantly increase AR, FKBP5 and PHLPP expressions, therefore inhibit p-Akt (S473) and p-ERK (Thr202/Tyr204) in SKhep1 and HA22T cells. (c), left and middle
panel, IVIS imaging in mice was used to determine the intrahepatic metastasis and lung metastasis, and lower intra-hepatic and lung metastasis occurrence in miR-367-3p-expressing
group than control group with or without Sorafenib treatment were found. Right panel, total metastatic foci were counted after sacriﬁce, and less total metastatic foci in miR-367-3p-
expressing group than control group with or without Sorafenib treatment were found. (d), representative bioluminescent images of intrahepatic metastasis and lung metastasis
(upper panel). HE staining conﬁrmed the tumor tissue in liver (left lower panel) and lung (right and middle lower panels). (e), representative bioluminescent images in different
groups after 2 months of orthotopic HCC xenograft (upper panel), and the total photon ﬂux were measured and analyzed using Living Image® software (PerkinElmer, lower panel),
showing less total tumor burden in miR-367-3p-expressing group than control group with or without Sorafenib treatment. (f), representative images of IHC staining for AR, p-Akt
(S473) and p-ERK (Thr202/Tyr204) in different treatment groups. p b 0.05 was considered statistically signiﬁcant. * p b 0.05, ** p b 0.01, and *** p b 0.001.
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66 J. Xu et al. / EBioMedicine 12 (2016) 55–67that miR-367-3p could directly target the 3′UTR #1 of MDM2 to de-
crease MDM2 protein levels. Interestingly, an early study showed that
MDM2 was a direct target of miR-25 and miR-32 (from the same
microRNA family as miR-367-3p) in glioblastoma multiforms (Suh
et al., 2012), with exactly the same sites predicted in that study as
those in the present study. However, we only identiﬁed the 1st predict-
ed site as the microRNA response element (MRE) mediating the silenc-
ing effect, but not the 2nd site, with 3 different HCC cell lines being
tested. Different disease models, different sources of tissue, different
ways of cloning anddifferent speciﬁcmicroRNAs are all possible reasons
for the varied results. Nevertheless, our data demonstrated that miR-
367-3p could directly target the 3′UTR of MDM2 to decrease MDM2
protein levels, which in turn increases AR protein expression. MDM2
is a RING ﬁnger-containing E3 ligase, which serves as the rate-limiting
step of protein ubiquitin modiﬁcation. An early study indicated that
the E3 ligase activity of MDM2 and phosphorylation of MDM2 by AKT
were essential for MDM2 to affect AR ubiquitination and degradation
(Lin et al., 2002). Indeed, in the present study, the MDM2 mediated
ubiquitination and degradation of AR were also observed in HCC.
The consequences of such increased AR protein levels may then
function through altering the downstream FKBP5/PHLPP signals, thus
dephosphorylating and deactivating AKT and ERK to inhibit the HCC
cell invasion. Although it is possible that miR-367-3p may suppress
HCC invasion through MDM2/p53 signals, our results indicate that p53
had little change or even decreased in HCC cells upon over-expressing
miR-367-3p. For MDM2 to degrade p53, there may be other factors in-
volved or required, but those factors are not there in this case. On the
other hand, miR-367-3p may have other effects besideMDM2 that ulti-
matelymay inﬂuence p53 levels. In brief, p53 is unlikely to play a role in
miR-367-3p regulated HCC invasion.
Although it was clear in the present study that miR-367-3p inhibits
HCC invasion, potential targets of miR-367-3p other than AR might
also play roles in regulating cell invasion and metastasis. For example,
miR-367-3p was recently reported to target Rab23, a member of the
RAS oncogene family, to inhibit the invasion and metastasis of gastric
cancer (Bin et al., 2015). Moreover, this miRNA can also potentially tar-
get oncoproteins like MAP2K4, SOX4 and FGF2, amongmany other pro-
teins, to negatively regulate HCC metastasis (Dweep and Gretz, 2015).
Nevertheless, our studies provided compelling evidence that MDM2/
AR signaling played a clear role in mediating HCC invasion. This is con-
sistentwith the central role of AR in regulatingHCC initiation and devel-
opment as HCC is one of several human malignancies exhibiting a clear
gender disparity (Clocchiatti et al., 2016).
We noted that the interaction and cross-talk amongAKT,MDM2 and
ARwere investigated in different contexts in previous studies (Lin et al.,
2002; Lee et al., 2015; McClurg et al., 2014), and here we provided the
evidence of a positive feedback loop linking all three components in
HCC cells (Fig. 5F). Furthermore, such a positive feedback loop also like-
ly contributes to an extensive and consistent elevation of AR in the con-
text of introducing miR-367-3p. Importantly, the combination of miR-
367-3p (to increase AR) and Sorafenib could better suppressHCC cell in-
vasion. Successful clinical application of these ﬁndings in the futuremay
help us to better retard HCC metastasis at late stages.
In conclusion, miR-367-3p might regulate the MDM2/AR-FKBP5/
PHLPP/(pAKT and pERK) signaling pathway, and miR-367-3p might
serve as a metastasis biomarker and possible novel candidate for thera-
peutic intervention for late-stage HCC, especially combinedwith amod-
erate dose of Sorafenib.
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